Urinary markers in the detection of bladder cancer: What's new?

Matthew E. Nielsen, Edward M. Schaeffer, Robert W. Veltri, Mark P. Schoenberg, Robert H. Getzenberg

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Bladder cancer is one of the most common genitourinary malignancies and is a potentially life-threatening diagnosis. For many patients, however, the diagnosis of bladder cancer entails a lifetime of vigilant, costly, and invasive surveillance for recurrent and/or progressive disease. In the context of relative limitations of the current standard of cystoscopy and cytology, there has been burgeoning activity in the development of novel molecular urine-based markers for bladder cancer detection. RECENT FINDINGS: A large number of candidate bladder cancer biomarkers have emerged as our understanding of the molecular pathogenesis of the disease has evolved. Many of these are in the relatively earlier phases of development but several have received the approval of the United States Food and Drug Administration for clinical use and are already being applied to patients in clinical practice. SUMMARY: Urine-based markers for bladder cancer detection represent an area of substantial innovation and discovery with potentially profound scientific, clinical, and economic implications. As more of these tests become standardized and undergo evaluation in large multicenter trials, it is conceivable that a novel marker or panel of markers will emerge as a major enhancement to the current standard of care.

Original languageEnglish (US)
Pages (from-to)350-355
Number of pages6
JournalCurrent Opinion in Urology
Volume16
Issue number5
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Urine
Cystoscopy
United States Food and Drug Administration
Standard of Care
Tumor Biomarkers
Multicenter Studies
Cell Biology
Economics
Neoplasms

Keywords

  • Bladder cancer
  • Detection
  • Markers
  • Surveillance
  • Urine

ASJC Scopus subject areas

  • Urology

Cite this

Urinary markers in the detection of bladder cancer : What's new? / Nielsen, Matthew E.; Schaeffer, Edward M.; Veltri, Robert W.; Schoenberg, Mark P.; Getzenberg, Robert H.

In: Current Opinion in Urology, Vol. 16, No. 5, 09.2006, p. 350-355.

Research output: Contribution to journalArticle

Nielsen, Matthew E. ; Schaeffer, Edward M. ; Veltri, Robert W. ; Schoenberg, Mark P. ; Getzenberg, Robert H. / Urinary markers in the detection of bladder cancer : What's new?. In: Current Opinion in Urology. 2006 ; Vol. 16, No. 5. pp. 350-355.
@article{0d0592b6606540738871b09e76a37f6e,
title = "Urinary markers in the detection of bladder cancer: What's new?",
abstract = "PURPOSE OF REVIEW: Bladder cancer is one of the most common genitourinary malignancies and is a potentially life-threatening diagnosis. For many patients, however, the diagnosis of bladder cancer entails a lifetime of vigilant, costly, and invasive surveillance for recurrent and/or progressive disease. In the context of relative limitations of the current standard of cystoscopy and cytology, there has been burgeoning activity in the development of novel molecular urine-based markers for bladder cancer detection. RECENT FINDINGS: A large number of candidate bladder cancer biomarkers have emerged as our understanding of the molecular pathogenesis of the disease has evolved. Many of these are in the relatively earlier phases of development but several have received the approval of the United States Food and Drug Administration for clinical use and are already being applied to patients in clinical practice. SUMMARY: Urine-based markers for bladder cancer detection represent an area of substantial innovation and discovery with potentially profound scientific, clinical, and economic implications. As more of these tests become standardized and undergo evaluation in large multicenter trials, it is conceivable that a novel marker or panel of markers will emerge as a major enhancement to the current standard of care.",
keywords = "Bladder cancer, Detection, Markers, Surveillance, Urine",
author = "Nielsen, {Matthew E.} and Schaeffer, {Edward M.} and Veltri, {Robert W.} and Schoenberg, {Mark P.} and Getzenberg, {Robert H.}",
year = "2006",
month = "9",
doi = "10.1097/01.mou.0000240308.62958.50",
language = "English (US)",
volume = "16",
pages = "350--355",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Urinary markers in the detection of bladder cancer

T2 - What's new?

AU - Nielsen, Matthew E.

AU - Schaeffer, Edward M.

AU - Veltri, Robert W.

AU - Schoenberg, Mark P.

AU - Getzenberg, Robert H.

PY - 2006/9

Y1 - 2006/9

N2 - PURPOSE OF REVIEW: Bladder cancer is one of the most common genitourinary malignancies and is a potentially life-threatening diagnosis. For many patients, however, the diagnosis of bladder cancer entails a lifetime of vigilant, costly, and invasive surveillance for recurrent and/or progressive disease. In the context of relative limitations of the current standard of cystoscopy and cytology, there has been burgeoning activity in the development of novel molecular urine-based markers for bladder cancer detection. RECENT FINDINGS: A large number of candidate bladder cancer biomarkers have emerged as our understanding of the molecular pathogenesis of the disease has evolved. Many of these are in the relatively earlier phases of development but several have received the approval of the United States Food and Drug Administration for clinical use and are already being applied to patients in clinical practice. SUMMARY: Urine-based markers for bladder cancer detection represent an area of substantial innovation and discovery with potentially profound scientific, clinical, and economic implications. As more of these tests become standardized and undergo evaluation in large multicenter trials, it is conceivable that a novel marker or panel of markers will emerge as a major enhancement to the current standard of care.

AB - PURPOSE OF REVIEW: Bladder cancer is one of the most common genitourinary malignancies and is a potentially life-threatening diagnosis. For many patients, however, the diagnosis of bladder cancer entails a lifetime of vigilant, costly, and invasive surveillance for recurrent and/or progressive disease. In the context of relative limitations of the current standard of cystoscopy and cytology, there has been burgeoning activity in the development of novel molecular urine-based markers for bladder cancer detection. RECENT FINDINGS: A large number of candidate bladder cancer biomarkers have emerged as our understanding of the molecular pathogenesis of the disease has evolved. Many of these are in the relatively earlier phases of development but several have received the approval of the United States Food and Drug Administration for clinical use and are already being applied to patients in clinical practice. SUMMARY: Urine-based markers for bladder cancer detection represent an area of substantial innovation and discovery with potentially profound scientific, clinical, and economic implications. As more of these tests become standardized and undergo evaluation in large multicenter trials, it is conceivable that a novel marker or panel of markers will emerge as a major enhancement to the current standard of care.

KW - Bladder cancer

KW - Detection

KW - Markers

KW - Surveillance

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=33747172001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747172001&partnerID=8YFLogxK

U2 - 10.1097/01.mou.0000240308.62958.50

DO - 10.1097/01.mou.0000240308.62958.50

M3 - Article

C2 - 16905981

AN - SCOPUS:33747172001

VL - 16

SP - 350

EP - 355

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -